| Autor: |
Liyan Mao, LaCourse, Sylvia M., Soyeon Kim, Liu, Chang, Ning, Bo, Bao, Duran, Fan, Jia, Lyon, Christopher J., Ziyong Sun, Nachman, Sharon, Mitchell, Charles D., Hu, Tony Y. |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.6084/m9.figshare.14609285.v1 |
| Popis: |
Additional file 1: Table S1. Comparison of the baseline demographics and clinical characteristics of P1041 participants excluded and included for evaluation by the serum CFP-10pep assay. Table S2. The distribution of participants who received INH versus placebo by HIV status and TB category. Table S3. Summary of sera available per child and their distribution by group. Table S4. Sera distribution by group and time to TB diagnosis or diagnosis window. Table S5. Distribution of Unconfirmed TB evidence among included/excluded infants. Table S6. Distribution of Unconfirmed TB evidence and CFP-10pep assay positivity rates. Table S7. CFP-10pep sensitivity among children who received INH versus placebo by HIV and Mtb infection status. Table S8. CFP-10pep specificity among children who received INH versus placebo by HIV and Mtb infection status. Table S9. Comparision of the diagnostic subgroups and classification criteria used in the P1041 protocol and the 2015 NIH pediatric TB guidelines. Table S10. Cross-classification of analyzed children by P1041 and 2015 NIH criteria. Fig. S1. Age distribution at time of TB diagnosis. Fig. S2. Venn diagrams for the availability and TB diagnostic contribution of clinical data. Fig. S3. Serum CFP-10pep signal distribution by HIV infection status and TB diagnosis category and distribution of positive TB diagnostic results and CPF-10pep signal relative to TB diagnosis. Fig. S4. Positive proportions of CFP-10pep, culture and smear results relative to TB diagnosis time. Fig. S5. Changes in serum CFP-10pep levels from pre-diagnosis to post-treatment initiation in representative TB cases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
